Drug target · SLC6A3
DAT
Dopamine transporter
7 compounds in the CNS pipeline act on DAT.
Compounds targeting DAT
| Compound | Action | Affinity | Lead program | Developer |
|---|---|---|---|---|
| CentanafadineSmall molecule | Reuptake inhibitor | IC50 38 nM | ApprovedAttention-deficit/hyperactivity disorder | Otsuka Pharmaceutical Co., Ltd. |
| Solriamfetol (Sunosi)Small molecule | Reuptake inhibitor | Ki 14200 nM | ApprovedExcessive daytime sleepiness | Axsome Therapeutics, Inc. |
| Ammoxetine (S-071031B)Small molecule | Inhibitor | — | Phase 3Major depressive disorder | CSPC ZhongQi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. |
| Methylone (TSND-201)Psychedelic | Releaser | — | Phase 3Post-traumatic stress disorder | Transcend Therapeutics, Inc. |
| DT402Psychedelic | Releaser | EC50 3700 nM | Phase 2Autism spectrum disorder | Definium Therapeutics, Inc. |
| EMP-01 (oral R-MDMA)Psychedelic | Releaser | — | Phase 2Social anxiety disorder | EmpathBio, Inc. |
| OPC-64005Small molecule | Reuptake inhibitor | — | DiscontinuedMajor depressive disorder | Otsuka Pharmaceutical Co., Ltd. |